| GC30923-10mg |
|
794568-92-6 |
BAY 73-6691 ((R)-BAY 73-6691)
|
0 |
C15H12ClF3N4O |
|
|
|
| GC30923-5mg |
|
794568-92-6 |
BAY 73-6691 ((R)-BAY 73-6691)
|
0 |
C15H12ClF3N4O |
|
|
|
| GC30922-50mg |
|
330461-64-8 |
SIRT2 Inhibitor II (AK-1)
|
0 |
C19H21N3O5S |
|
|
|
| GC30922-25mg |
|
330461-64-8 |
SIRT2 Inhibitor II (AK-1)
|
0 |
C19H21N3O5S |
|
|
|
| GC30922-10mg |
|
330461-64-8 |
SIRT2 Inhibitor II (AK-1)
|
0 |
C19H21N3O5S |
|
|
|
| GC30922-5mg |
|
330461-64-8 |
SIRT2 Inhibitor II (AK-1)
|
0 |
C19H21N3O5S |
|
|
|
| GC30922-10mM(1mLinDMSO) |
|
330461-64-8 |
SIRT2 Inhibitor II (AK-1)
|
0 |
C19H21N3O5S |
|
|
|
| GC30921-100mg |
|
52-51-7 |
|
0 |
C3H6BrNO4 |
|
|
|
| GC30921-10mM(1mLinDMSO) |
|
52-51-7 |
|
0 |
C3H6BrNO4 |
|
|
|
| GC30920-100mg |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30920-50mg |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30920-10mg |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30920-5mg |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30920-1mg |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30920-10mM(1mLinDMSO) |
|
677746-25-7 |
|
0 |
C15H14BrN |
|
|
|
| GC30919-100mg |
|
304-84-7 |
|
0 |
C12H17NO3 |
|
|
|
| GC30919-10mM(1mLinDMSO) |
|
304-84-7 |
|
0 |
C12H17NO3 |
|
|
|
| GC30918-100mg |
|
443103-97-7 |
A2A receptor antagonist 1
|
0 |
C16H12FN5O |
|
|
|
| GC30918-50mg |
|
443103-97-7 |
A2A receptor antagonist 1
|
0 |
C16H12FN5O |
|
|
|
| GC30918-10mg |
|
443103-97-7 |
A2A receptor antagonist 1
|
0 |
C16H12FN5O |
|
|
|
